With 0.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.6 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $5.34 whereas the lowest price it dropped to was $5.09. The 52-week range on CTKB shows that it touched its highest point at $9.87 and its lowest point at $3.80 during that stretch. It currently has a 1-year price target of $8.10. Beta for the stock currently stands at 1.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTKB was up-trending over the past week, with a rise of 6.34%, but this was up by 2.77% over a month. Three-month performance dropped to -7.47% while six-month performance fell -19.00%. The stock gained 21.21% in the past year, while it has lost -42.98% so far this year. A look at the trailing 12-month EPS for CTKB yields -0.13 with Next year EPS estimates of 0.13. For the next quarter, that number is 0.01. This implies an EPS growth rate of -89.56% for this year and 940.46% for next year.
Float and Shares Shorts:
At present, 130.71 million CTKB shares are outstanding with a float of 119.40 million shares on hand for trading. On 2024-10-15, short shares totaled 4.47 million, which was 340.00000000000006 higher than short shares on 1726185600. In addition to Dr. Wenbin Jiang Ph.D. as the firm’s President, CEO & Chairman of the Board, Dr. Ming Yan Ph.D. serves as its CTO & Director.
Institutional Ownership:
Through their ownership of 0.58042 of CTKB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CTKB reported revenue of $46617000.0 and operating income of -$8527000.0. The EBITDA in the recently reported quarter was -$4572000.0 and diluted EPS was -$0.08.
